How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

202 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. Full Text available with Trip Pro

Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. Ciclopirox is a topical antifungal agent of the hydroxypyridone class whose mode of action is poorly understood. In order to elucidate the mechanism of action of ciclopirox, we analysed the growth, cellular integrity, biochemical properties, viability and transcriptional profile of the polymorphic yeast Candida albicans following exposure to this antifungal agent.Multiple (...) , (ii) in media that lacked glucose, and (iii) for cells that were pre-incubated with hydrogen peroxide or menadione [which caused induction of proteins involved in detoxification of reactive oxygen species (ROS)]. In contrast, cells pre-cultured under poor oxygen conditions (which had decreased activity of proteins involved in ROS detoxification) were more susceptible to ciclopirox. Treatment with ciclopirox did not directly cause cell membrane damage and did not change intracellular levels of ATP

2005 Journal of Antimicrobial Chemotherapy

182. Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. Full Text available with Trip Pro

Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. The aim of this study was to identify changes in the gene expression profile of Candida albicans upon exposure to the hydroxypyridone anti-infective agent ciclopirox olamine in an effort to better understand its mechanism of action.C. albicans SC5314 was exposed to either medium alone or ciclopirox olamine at a concentration equivalent to the IC50 (0.24 mg/L) for 3 h. RNA was isolated and gene expression (...) profiles were compared using DNA microarrays. Differential expression of select genes was confirmed by real-time reverse transcription (RT)-PCR. Mutants disrupted for CDR2 and both CDR1 and CDR2, as well as a clinical isolate overexpressing CDR1 and CDR2, were examined for changes in susceptibility to ciclopirox olamine.A total of 49 genes were found to be responsive to ciclopirox olamine, including 36 up-regulated genes and 13 down-regulated genes. These included genes involved in small molecule

2005 Journal of Antimicrobial Chemotherapy

183. Ototoxic Effect of Topical Ciclopirox as an Antimycotic Preparation. (Abstract)

Ototoxic Effect of Topical Ciclopirox as an Antimycotic Preparation. To evaluate the ototoxicity of ciclopirox-containing solution as an otologic preparation for the treatment of otomycosis.Ciclopirox is a synthetic antimycotic agent available in a variety of formulations to treat superficial fungal infections. Ciclopirox has demonstrated both fungicidal and fungistatic activity in vitro against a broad spectrum of pathogenic fungi. It also possesses a broad-spectrum antibacterial properties (...) , anti-inflammatory, and antiedema effect. The ototoxic effect of ciclopirox-containing solutions has not been known, so the current study was designed to observe the ototoxic effect of this solution experimentally.Experiments were performed in 22 young male albino guinea pigs (weight, 450-550 g). The 10 animals in the experimental group received ciclopirox solution, and the control group was divided into two groups of six animals each. The first group received saline solution (negative control

2008 Otology and Neurotology

184. Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. (Abstract)

Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. Seborrheic dermatitis is a chronic superficial fungal infection of the skin, particularly affecting sites rich in sebaceous glands. Although the precise etiology of seborrheic dermatitis is uncertain, yeasts of the genus Malassezia are known to play a causative role. Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent, which also has anti-inflammatory properties. Ciclopirox is effective both (...) in vitro and in vivo against Malassezia yeasts, making it a valuable option for the treatment of seborrheic dermatitis. Varying frequencies and concentrations of ciclopirox shampoo have been shown to be effective and safe in the treatment of seborrheic dermatitis of the scalp.

2006 International Journal of Dermatology

185. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. (Abstract)

Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. The efficacy and safety of a new antimycotic agent, ciclopirox olamine, were evaluated in two multicenter, randomized, double-blind trials in patients with clinically and mycologically diagnosed cutaneous candidosis. Patients applied the assigned drug twice daily for 28 days. In the first comparison, significantly better clinical and mycological results were obtained in the 74 patients treated (...) with ciclopirox olamine than in the 70 patients treated with the vehicle only. The highly significant differences between treatment groups persisted through the final visit, two weeks posttreatment. In the second study, after one, two, and three weeks of treatment, significantly better clinical responses were seen in the 48 patients treated with ciclopirox olamine than in the 48 treated with clotrimazole. Mycological responses, however, were similar in the two treatment groups over the four-week treatment

1985 Clinical therapeutics Controlled trial quality: uncertain

186. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. (Abstract)

Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Two randomized, double-blind, parallel-group studies, each conducted at five medical centers, assessed the efficacy and safety of a new antifungal agent, ciclopirox olamine cream 1%, in patients with tinea versicolor. In one study, the antifungal agent was compared with its cream vehicle; in the other, it was compared with another antifungal compound, 1% clotrimazole cream. In both studies, treatments were (...) applied twice daily for 14 days. Results with ciclopirox olamine cream were significantly better (P less than 0.05) than those with the vehicle alone after one and two weeks of therapy and at one and two weeks posttherapy. After two weeks of treatment, 49% of the 73 patients treated with the antifungal cream were clinically and mycologically cured, whereas only 24% of the 72 patients using the vehicle were similarly cured (P less than 0.001). The clinical cure rate with ciclopirox olamine cream also

1985 Clinical therapeutics Controlled trial quality: uncertain

187. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. (Abstract)

Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. In separate multicentre, randomized, double-blind clinical trials, 1% ciclopirox olamine cream was compared with its cream vehicle and with 1% clotrimazole cream as treatment for tinea corporis and tinea cruris. Patients who demonstrated clinical and mycological findings consistent with the diagnoses of tinea corporis or tinea cruris were included in the study. Clinical (...) and mycological evaluations were made pretreatment, at the end of each of the four weeks of treatment, and weekly for the two weeks immediately following cessation of treatment. In both studies, use of ciclopirox olamine cream resulted in demonstrable improvements after the first week of therapy and in complete clinical and mycological clearing in two thirds of the patients at the end of the treatment period. These results were maintained through the two-week drug-free observation period that followed the end

1986 The Journal of international medical research Controlled trial quality: uncertain

188. [Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. (Abstract)

[Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. Anti-inflammatory actions of ciclopirox, an antifungal agent, have been described previously. We assessed the effectiveness of ciclopirox in the treatment of viral warts.Twenty-three immunocompetent patients (age 9-61 years) with common warts at the hands, feet and in the face resistant to conventional therapy were treated. Following keratolysis with a salicylic acid-containing patch, an 8% ciclopirox (...) lacquer was applied 1-2 times daily. At the beginning and the end of the treatment lesions were photographed and the time span (minimum 4 weeks) until complete resolution was documented.In 7 patients complete remission, and in 12 patients partial remission was achieved. Only 4 patients did not show any effect under topical ciclopirox treatment (mean duration of therapy 3.2 +/- 2.1 months). The overall response rate was 82.6%. Local side effects like erythema or pruritus were not reported.Our data

2001 Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete

189. Ciclopirox gel for seborrheic dermatitis of the scalp. (Abstract)

Ciclopirox gel for seborrheic dermatitis of the scalp. Seborrheic dermatitis is a common inflammatory skin disorder that usually occurs in patients with pre-existing seborrhea. The etiology of seborrheic dermatitis is uncertain. Typically, sites dense with sebaceous glands support growth of the lipophilic yeast Malassezia furfur. Ciclopirox (Loprox) gel is a hydroxypyridone, broad-spectrum antifungal agent proven effective against the yeast M. furfur.A multicenter, randomized, double-blind (...) , vehicle controlled study of 178 subjects evaluated the efficacy of ciclopirox gel in treating seborrheic dermatitis of the scalp.One hundred and seventy-eight subjects were randomized to apply either ciclopirox gel 0.77% twice daily, or vehicle twice daily for 28 days. Subjects' signs and symptoms of severity (erythema, scaling, pruritus and burning) were rated on a scale of 0-3 (none to severe); for inclusion, a minimum score of 4, for the sum of the individual ratings was required. Efficacy

2003 International journal of dermatology Controlled trial quality: uncertain

190. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. (Abstract)

Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. Ciclopirox 8% nail lacquer has recently become the first topical antifungal agent to be approved by the US Food and Drug Administration for the treatment of onychomycosis. This article reviews the results of the two pivotal clinical trials of this drug that have been performed in the United States as well as those that have been carried out in other countries. The two US studies were both double (...) -blind, vehicle-controlled, parallel-group, multicenter studies designed to determine the efficacy and safety of ciclopirox nail lacquer in the treatment of mild-to-moderate onychomycosis of the toenails caused by dermatophytes. The combined results show a 34% mycologic cure rate, as compared with 10% for the placebo. Data from the ten studies conducted worldwide show a meta-analytic mean (+/- SE) mycologic cure rate of 52.6% +/- 4.2%. As expected for a topical agent, ciclopirox nail lacquer

2001 Journal of the American Podiatric Medical Association Controlled trial quality: uncertain

191. [Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis]. (Abstract)

[Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis]. A multicenter randomized study was performed. One hundred and seventy patients were selected. The patients were 18 years and older. They presented signs and symptoms of genital candidiasis and had positive smear culture for Candida. Eighty five patients were assigned to receive Cicloprox olamine 1%, and eighty five patients were assigned to receive

2000 Ginecología y obstetricia de México Controlled trial quality: uncertain

192. Ciclopirox gel in the treatment of patients with interdigital tinea pedis. (Abstract)

Ciclopirox gel in the treatment of patients with interdigital tinea pedis. BACKGROUND Tinea pedis (athlete's foot) is the most common fungal infection in the general population. Ciclopirox, a broad-spectrum hydroxypyridone antifungal, has proven efficacy against the organisms commonly implicated in tinea pedis; Trichophyton rubrum, T.mentagrophytes and Epidermophyton floccosum.Two multicenter, double-blind, clinical studies compared the efficacy and safety of ciclopirox gel with that of its (...) vehicle base in subjects with moderate interdigital tinea pedis with or without plantar involvement.Three hundred and seventy-four subjects were enrolled and randomized to one of two treatment groups: ciclopirox gel 0.77%, or ciclopirox gel vehicle, applied twice daily for 28 days, with a final visit up to day 50. The primary efficacy variable was Treatment Success defined as combined mycological cure and clinical improvement >/= 75%. Secondary measures of effectiveness were Global Clinical Response

2003 International journal of dermatology Controlled trial quality: uncertain

193. Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. (Abstract)

Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. Dandruff is a chronic scalp condition characterized by scaling. The common causative agent is now accepted to be the lipophilic yeast Malassezia furfur. Ketoconazole, a highly effective antifungal agent against M. furfur has been used for the treatment of dandruff.To determine whether a 1.5% ciclopirox olamine shampoo is as effective as a 2% ketoconazole shampoo for the treatment of mild to moderate dandruff.A total (...) of 64 patients, with mild to moderate dandruff, participated in the study. The study consisted of three consecutive phases: a 2-week washout period, a 4-week treatment period and a 2-week post-treatment period. Patients were randomized equally to either the 1.5% ciclopirox olamine shampoo or 2% ketoconazole shampoo. An overall dandruff score was calculated using an area of dandruff involvement score and a severity score. Patients evaluated the presence of pruritus and also reported a global

2003 Journal of Dermatological Treatment Controlled trial quality: uncertain

194. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis (Abstract)

A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis The association between seborrhoeic dermatitis and dandruff and the yeast Malassezia furfur is well recognized. Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective (...) treatment for these scalp conditions. Salicylic acid has keratolytic properties and aids in the removal of scales.To compare the therapeutic efficacy of a shampoo containing 1.5% ciclopirox olamine and 3% salicylic acid (CPO/SA) with Nizoral (2.0% ketoconazole shampoo) in a study involving 154 subjects with dandruff - 70 of whom also had seborrhoeic dermatitis of the scalp. Nizoral is currently a registered treatment for dandruff and seborrhoeic dermatitis.The shampoos were used three times week for 4

2002 Journal of Dermatological Treatment Controlled trial quality: uncertain

195. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Full Text available with Trip Pro

Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. The hydroxypyridone ciclopirox olamine belongs to the antimycotic drugs used for the treatment of superficial mycoses. In contrast to the azoles and other antimycotic drugs, its specific mode of action is only poorly understood. To investigate the mode of action of ciclopirox olamine on fungal viability, pathogenicity, and drug (...) resistance, we examined the expression patterns of 47 Candida albicans genes in cells grown in the presence of a subinhibitory concentration (0.6 micro g/ml) of ciclopirox olamine by reverse transcription-PCR. In addition, we used suppression-subtractive hybridization to further identify genes that are up-regulated in the presence of ciclopirox olamine. The expression of essential genes such as ACT1 was not significantly modified in cells exposed to ciclopirox olamine. Most putative and known virulence

2003 Antimicrobial Agents and Chemotherapy

196. Ciclopirox for the treatment of superficial fungal infections: a review. (Abstract)

Ciclopirox for the treatment of superficial fungal infections: a review. Ciclopirox is a broad-spectrum antifungal agent that also exhibits anti-inflammatory and antibacterial activity. The lotion and cream formulations of ciclopirox are effective in many types of infection, including tinea corporis/cruris, tinea pedis, cutaneous candidiasis, pityriasis (tinea) versicolor, and seborrheic dermatitis. The new ciclopirox gel 0.77% formulation is also indicated for the treatment of seborrheic

2003 International Journal of Dermatology

197. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. (Abstract)

Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. In many instances, a cutaneous fungal infection may exist concomitantly with bacterial involvement. In this study we compared the in vitro activity of three antifungal agents against the dermatophytes, yeasts and bacteria recovered most commonly from cutaneous mycoses and bacterial infections.Using a microdilution method adapted from the National Committee (...) for Clinical Laboratory Standards (NCCLS), we determined the minimum inhibitory concentrations (MICs) of ciclopirox olamine, econazole nitrate and butenafine HCl against a panel of dermatophyte fungi and yeasts (n = 39) and bacterial isolates (n = 45).All three antifungals demonstrated comparable activity against the dermatophytes tested, with a MIC range of 0.03-0.25 micro g/ml for ciclopirox, < 0.001-0.25 micro g/ml for econazole and 0.03-0.25 micro g/ml for butenafine. For yeasts, ciclopirox showed

2003 International Journal of Dermatology

198. Interdigital tinea pedis (dermatophytosis simplex and complex) and treatment with ciclopirox 0.77% gel. (Abstract)

Interdigital tinea pedis (dermatophytosis simplex and complex) and treatment with ciclopirox 0.77% gel. The most common presentation of tinea pedis (athlete's foot) is that involving the interdigital spaces. Tinea pedis interdigitalis may present as asymptomatic dermatophytosis simplex or dermatophytosis complex, which is symptomatic, with secondary bacterial infection. In the dermatophytosis complex presentation there may be inflammation, maceration and odor, with bacterial involvement (...) . Ciclopirox gel offers advantages in the treatment of tinea pedis, especially in the dermatophytosis complex presentation, with antifungal, antibacterial, and anti-inflammatory activity; furthermore, the gel formulation is fast drying, which is an advantage when the toe web area is moist.

2003 International Journal of Dermatology

199. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. (Abstract)

In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. With the development of newer antifungal agents with activity against both yeasts and filamentous fungi, there is an increased need to develop and standardize in vitro assays that will evaluate the activity of antimycotics against filamentous fungi. In vitro analysis of antifungal activity (...) of these agents would also allow for the comparison between different antimycotics, which in turn may clarify the reasons for lack of clinical response or serve as an effective therapy for patients with chronic infection.To determine the in vitro susceptibility of fungal organisms to ciclopirox, terbinafine, ketoconazole and itraconazole and to evaluate the in vitro activity and mode of interaction of ciclopirox in combination with either terbinafine or itraconazole.In the minimum inhibitory concentration

2003 British Journal of Dermatology

200. Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis

Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>